Zimmermann, Tobias
Kaufmann, Philip
Amacher, Simon A.
Sutter, Raoul
Loosen, Gregor
Merdji, Hamid
Helms, Julie
Todorov, Atanas
Gebert, Pimrapat
Regitz-Zagrosek, Vera
Gebhard, Catherine
Singer, Mervyn
Siegemund, Martin
Gebhard, Caroline E.
,
Funding for this research was provided by:
University of Basel
Article History
Received: 11 March 2024
Accepted: 19 June 2024
First Online: 27 June 2024
Declarations
:
: In the annual assembly in autumn 2015, the members of the SSICM agreed that all pseudonymized data from the MDSi can be used for research, once a specific request has been approved by the appropriate scientific committee. The Ethics committee of Northwestern Switzerland approved this procedure (EKNZ UBE-15/47). The scientific committee of the SSICM approved the study with the above-mentioned title.
: Not applicable.
: TZ has received research grants by the Swiss National Science Foundation (SNSF, Grant No. P500PM_214203) and the Freiwillige Akademische Gesellschaft Basel, outside the submitted work. SAA has received grants from the Mach-Gaensslen Foundation, Switzerland, and the Nora van Meeuwen-Haefliger Foundation of the University of Basel, Switzerland, outside the present work. RS has received research grants from the Swiss National Foundation (No. 320030_169379), the Research Fund of the University Basel, the Scientific Society Basel, and the Gottfried Julia Bangerter-Rhyner Foundation. He received personal grants from UCB-pharma and holds stocks from Novartis and Roche. JH has received honoraria for lectures from Diagnostica Stago, Pfizer PFE France, Sanofi Aventis France, Inotrem, MSD and Shionogi and Asahi Kasei. CG has received research grants and speaker’s fees from the Novartis Foundation, from Sanofi Genzyme, Switzerland, and Bayer Pharmaceuticals outside of the submitted work. MeS has received research grants from the Medical Research Council, EU, UK NIHR, Rosetrees Trust, Wellcome Trust and Gentian. Consulting fees paid to himself or institution have been received from Safeguard Biosystems, deePull, Matisse Pharmaceuticals, Volition, Aptarion, Roche Diagnostics, NewB and Deltex Medical and speaker fees from AOP Pharma, Fresenius and Biomerieux. All are outside of the submitted work. CEG was supported by the research fund of the Intensive Care Unit, University Hospital Basel.